Methods of colonizing a microbiome, treating and/or preventing inflammatory bowel disease and graft versus host disease
AssigneeVedanta Biosciences, Inc.
InventorsEmily Crossette, Bernat Olle
Life of this patent
Estimating the term…
Abstract
The disclosure relates to methods for colonizing a microbiome, by administering pharmaceutical compositions comprising a purified bacterial mixture to the subject. Also provided are methods for treating and/or preventing inflammatory bowel disease, methods for reducing the risk of inflammatory bowel disease and/or reducing the occurrence of inflammatory bowel disease in a subject by administering pharmaceutical compositions comprising a purified bacterial mixture to the subject. Also provided are methods for treating and/or preventing graft versus host disease in a subject by administering pharmaceutical compositions comprising a purified bacterial mixture to the subject.
Claims294
A method for colonizing a microbiome in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a purified bacterial mixture comprising two or more bacterial strains of species selected from the group consisting of Clostridium saccharogumia, Flavonifractor plautii, Clostridium hathewayi, Blautia coccoides, Clostridium bolteae, Clostridium indolis, Anaerotruncus colihominis, Ruminococcus sp., Clostridium lavalense, Clostridium symbiosum, Clostridium ramosum, Eubacterium contortum, Clostridium scindens, Lachnospiraceae bacterium, Clostridium sp., and Lachnospiraceae bacterium.
A method for colonizing a microbiome in a subject, the method comprising administering to the subject a therapeutically effective of a pharmaceutical composition comprising a purified bacterial mixture comprising two or more bacterial strains that comprise 16S rDNA sequences of at least 97% sequence identity to the nucleic acid sequences set forth as SEQ ID NOs:
- 1-16.
A method for treating and/or preventing inflammatory bowel disease (IBD) in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a purified bacterial mixture comprising two or more bacterial strains of species elected from the group consisting of Clostridium saccharogumia, Flavonifractor plautii, Clostridium hathewayi, Blautia coccoides, Clostridium bolteae, Clostridium indolis, Anaerotruncus colihominis, Ruminococcus sp., Clostridium lavalense, Clostridium symbiosum, Clostridium ramosum, Eubacterium contortum, Clostridium scindens, Lachnospiraceae bacterium, Clostridium sp., and Lachnospiraceae bacterium.
A method for treating and/or preventing inflammatory bowel disease (IBD) in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a purified bacterial mixture comprising two or more bacterial strains that comprise 16S rDNA sequences of at least 97% sequence identity to the nucleic acid sequences set forth as SEQ ID NOs:
- 1-16.
A method for reducing risk and/or occurrence of inflammatory bowel disease (IBD) in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a purified bacterial mixture comprising two or more bacterial strains of species elected from the group consisting of Clostridium saccharogumia, Flavonifractor plautii, Clostridium hathewayi, Blautia coccoides, Clostridium bolteae, Clostridium indolis, Anaerotruncus colihominis, Ruminococcus sp., Clostridium lavalense, Clostridium symbiosum, Clostridium ramosum, Eubacterium contortum, Clostridium scindens, Lachnospiraceae bacterium, Clostridium sp., and Lachnospiraceae bacterium.
A method for reducing risk and/or occurrence of inflammatory bowel disease (IBD) in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a purified bacterial mixture comprising two or more bacterial strains that comprise 16S rDNA sequences of at least 97% sequence identity to the nucleic acid sequences set forth as SEQ ID NOs:
- 1-16.
A method for treating and/or preventing graft versus host disease (GvHD) in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a purified bacterial mixture comprising two or more bacterial strains of species selected from the group consisting of Clostridium saccharogumia, Flavonifractor plautii, Clostridium hathewayi, Blautia coccoides, Clostridium bolteae, Clostridium indolis, Anaerotruncus colihominis, Ruminococcus sp., Clostridium lavalense, Clostridium symbiosum, Clostridium ramosum, Eubacterium contortum, Clostridium scindens, Lachnospiraceae bacterium, Clostridium sp., and Lachnospiraceae bacterium.
A method for treating and/or preventing graft versus host disease (GvHD) in a subject, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a purified bacterial mixture comprising two or more bacterial strains that comprise 16S rDNA sequences of at least 97% sequence identity to the nucleic acid sequences set forth as SEQ ID NOs:
- 1-16.
The method of any one of claims 186-2223, wherein a dose of the pharmaceutical composition comprises between 108 to 1011 total colony forming units (CFUs).
A method, comprising administering to a subject a therapeutically effective amount of a pharmaceutical composition in a loading period followed by administering to the subject a therapeutically effective amount of the pharmaceutical composition a maintenance period, wherein the pharmaceutical composition comprises a purified bacterial mixture comprising two or more bacterial strains of species selected from the group consisting of Clostridium saccharogumia, Flavonifractor plautii, Clostridium hathewayi, Blautia coccoides, Clostridium bolteae, Clostridium indolis, Anaerotruncus colihominis, Ruminococcus sp., Clostridium lavalense, Clostridium symbiosum, Clostridium ramosum, Eubacterium contortum, Clostridium scindens, Lachnospiraceae bacterium, Clostridium sp., and Lachnospiraceae bacterium.
A method, comprising administering to a subject a therapeutically effective amount of a pharmaceutical composition in a loading period followed by administering to the subject a therapeutically effective amount of the pharmaceutical composition a maintenance period, wherein the pharmaceutical composition comprises a purified bacterial mixture comprising two or more bacterial strains that comprise 16S rDNA sequences of at least 97% sequence identity to the nucleic acid sequences set forth as SEQ ID NOs:
- 1-16.
A method for assessing colonization of one or more bacterial strains of a bacterial composition in a microbiome of a subject, the method comprising
- isolating nucleic acid from a sample of the microbiome of the subject;
- and
- determining the presence of at least one bacterial strain of the bacterial composition by amplifying a nucleotide sequence of a genomic marker for the at least one the bacterial strains in the isolated nucleic acid;
- wherein if a genomic marker for a bacterial strain is present in the amplified nucleotide sequences, the microbiome is colonized with the bacterial strain.
Dependencies are inferred from the claim text.